$MSB

Mesabi Trust reported Q2 2026 revenue of $2.33M, a 57% decline year-over-year, and a net loss of $95K. The loss was attributed to a drop in royalty income due to lower pellet prices. The company reduced its quarterly distribution to $0.05 per unit.

Mesabi Trust (MSB) reported a Q2 net loss of $95,013, down from $4.74M a year earlier, due to lower royalty income and higher legal costs. Royalty income fell to $2.33M from $5.42M, with bonus royalties dropping to zero. The Trust cut its distribution to $0.05 per unit. Legal expenses increased due to ongoing arbitration with Northshore Mining and Cleveland-Cliffs. Pellet volumes rose slightly, but lower prices impacted royalties.

The Metals Royalty Company (TMCR) announced a US$165 million financing package, including a US$140 million convertible note offering and a US$25 million term loan, to fund the acquisition of an additional 1.0% royalty in the Mesabi iron ore project and repay existing debt. The transactions are expected to close on August 24, 2026, subject to conditions. The notes have an 8.00% coupon and a five-year maturity, while the loan has a 24-month term with a 12-month extension option.

Vietnam’s listed banks reported higher second-quarter 2026 net interest income versus the prior quarter, with only five banks declining. VietinBank led with a record VND20.7 trillion, first above VND20 trillion. BIDV, Vietcombank and VPBank also posted strong results. State Bank of Vietnam said system credit rose 8.38% to VND20.15 quadrillion by July 29.

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Announcement of Receipt of Quarterly Royalty Report and Royalty Payment On July 30, 2026, Mesabi Trust received the quarterly royalty report of iron ore shipments out of Silver Bay, Minnesota during the quarter ended June 3

Mesoblast (ASX: MSB) shares rose after the company said its Phase 3 MSB-DR004 trial for rexlemestrocel-L in chronic lower back pain reached its target of at least 300 treated patients. The randomized, placebo-controlled study compares an intradiscal injection vs sham and follows patients for 12 months. The update removes an execution risk and supports a regulatory catalyst timeline.

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. MESABI TRUST_July 14, 2026 0000065172 false 0000065172 2026-07-14 2026-07-14 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest e

The Metals Royalty Company (NASDAQ:TMCR) said its Mesabi Metallics royalty asset in Nashwauk, Minnesota completed its first production blast on July 10, 2026, fracturing about 211,000 tons of ore and opening the first pit ramp. TMCR expects ore to feed DR-grade pellets under a 1.0% index-priced gross overriding royalty with a revenue floor, targeting first pellet production in H2 2026 and potential annual royalty cash flow of about $11 million at 7.28 Mtpa.

Mesoblast (ASX: MSB) shares led ASX 200 gainers, up 4.91% to A$2.35, extending a two-week 24% rally. Bell Potter upgraded to Buy with a A$4.45 target. Mesoblast said it drew US$50m from a non-dilutive facility on June 25, and reported FDA BLA progress for Ryoncil (remestemcel-L) in late June and early July.

ASX futures pointed to a 0.49% rise at the open after Wall Street ended higher, supported by AI and chip stocks. The ASX 200 rose 0.5% on Friday to 8,806, led by mining and financials. Telstra fell 1.6%, WiseTech 1.8%, while Mesoblast rose 6% on US$115m FY2026 revenue. Geopolitical Iran tensions and oil moves weighed on sentiment.